Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.
A, F., F, P., I, M., MT, D., & GB, L. (2026). Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.. Medical sciences (Basel, Switzerland). https://doi.org/10.3390/medsci14030411
A F, F P, I M, MT D, GB L. Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.. Medical sciences (Basel, Switzerland). 2026; doi: 10.3390/medsci14030411
A F, F P, I M, et al. Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.[J]. Medical sciences (Basel, Switzerland). 2026. DOI: 10.3390/medsci14030411.
@article{a2026,
author = {Francica A and Perrone F and Maffei I and Denora MT and Luciani GB},
title = {Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis.},
journal = {Medical sciences (Basel, Switzerland)},
year = {2026},
doi = {10.3390/medsci14030411},
note = {PMID: 42506380},
}
TY - JOUR AU - Francica A AU - Perrone F AU - Maffei I AU - Denora MT AU - Luciani GB TI - Valve-Related Outcomes up to Six Years of a Next-Generation Bovine Pericardial Bioprosthesis Compared with Its Predecessor: A Propensity-Matched Analysis. T2 - Medical sciences (Basel, Switzerland) PY - 2026 DO - 10.3390/medsci14030411 AN - PMID:42506380 ER -
Background: Current ESC/EACTS guidelines recommend bioprosthetic valves for aortic valve replacement (AVR) in patients > 65 years, yet their use is increasing among younger individuals. The INSPIRIS Resilia (IR) valve, a next-generation bioprosthesis, was designed to improve durability and reduce structural valve degeneration (SVD). This study compares clinical and valve-related outcomes up to six years in patients undergoing AVR with either the IR or its predecessor, the Perimount Magna Ease (PME) valve. Methods: Between January 2017 and December 2023, 2053 patients underwent isolated or combined AVR at a single institution (1602 PME; 451 IR). Propensity-score matching identified 224 patient pairs with comparable baseline characteristics. Outcomes were assessed over follow-up extending up to six years, focusing on cardiovascular and valve-related adverse events. Transvalvular gradients were also assessed at follow-up. Results: After matching, mean age was 64.2 ± 7.7 years in both groups. Freedom from cardiovascular mortality at six years was similar between PME and IR (96.6% vs. 98.2%; p = 0.34), as were rates of stroke, rehospitalization, prosthetic valve endocarditis, and reintervention. A total of 12 PME (5.4%) and six IR valves (2.5%) were explanted during follow-up (p = 0.15), with prosthetic endocarditis representing the leading cause of reintervention. Only one case of severe SVD was observed in both groups. Conclusions: In patients undergoing AVR with comparable baseline risk profiles, IR and PME valves demonstrated similar clinical, valve-related, and hemodynamic outcomes up to six years of follow-up. Prosthetic valve endocarditis represented the leading cause of valve failure, whereas structural valve deterioration remained rare. Longer follow-up and a greater number of valve-related events will be necessary to determine whether differences in bioprosthetic valve degeneration emerge over time.